The recent SARAH and SIRveNIB trials looked to clarify the impact of SIRT versus sorafenib in patients with locally advanced HCC. What did they show? What are the implications for practice? And what other recent publications can help to shed light on this treatment question? The proceeding e-learning course will take you through our experts’ views on the results from these important studies.